ir_header
Current stock value

Last updated on Sep 19, 2014 3:30 PM ET

NASDAQ : SPHS 3.08   
- 0.02
  
0.65%

Fact Sheet

PDF Download the Sophiris Fact Sheet


Investor Presentation

PDF Download the Sophiris Investor Presentation


Investors

Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is currently enrolling patients in the PLUS 1 Phase III clinical study using PRX302 for the treatment of symptoms of BPH.

View all »   RSSRecent Releases

Sep 2, 2014
Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Aug 7, 2014
Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights

View all »Events & Presentations

Nov 18, 2014
Stifel Healthcare Conference